Online inquiry

IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ95MR)

This product GTTS-WQ95MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Breast Cancer, Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ95MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9822MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ5663MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDX-011
GTTS-WQ9215MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ9677MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ10921MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ14754MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ10249MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ7464MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GBR-830
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW